The invention relates to compositions and methods for treating nervous disorders. More particularly, the invention relates to methods of treating amyloÊd beta peptide-related disorders, particularly Alzheimer's disease, using Rac1 inhibitors. The invention may be used in mammalian subjects, particularly human subjects, at various stages of the disease, including disease onset. The invention also provides methods of producing, identifying, selecting or optimising compounds for use in the treatment of amyloÊd beta peptide-related disorders, based on a determination of the ability of a test compound to inhibit Rac 1.
本发明涉及治疗神经系统疾病的组合物和方法。更具体地说,本发明涉及使用Rac1
抑制剂治疗与淀粉样蛋白β肽相关的疾病,尤其是阿尔茨海默病的方法。本发明可用于哺乳动物受试者,尤其是人类受试者,在包括疾病起始阶段在内的各个疾病阶段。本发明还提供了基于测试化合物抑制Rac1的能力来生产、鉴定、选择或优化用于治疗淀粉样蛋白β肽相关疾病的化合物的方法。